Tao Sun

机构：Union Hospital, Capital Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Dalian University of Technology, Nanjing General Hospital of Nanjing Military Command, State Key Laboratory of Information Engineering in Surveying Mapping and Remote Sensing, Wuhan Union Hospital, Guang’anmen Hospital, Liaoning Cancer Hospital & Institute, Union Hospital, Beijing Obstetrics and Gynecology Hospital, Huazhong University of Science and Technology, China Medical University · ORCID：0000-0001-5931-386X

发表论文 166 篇 · 总被引 4117 次 · h-index 28

代表论文

• Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial (2025 · Nature Medicine · 被引 53)
• ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer (2025 · Signal Transduction and Targeted Therapy · 被引 29)
• Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort (2025 · Nature Communications · 被引 15)
• Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial (2025 · Nature Communications · 被引 10)
• Recent advances in copper sulfide nanoparticles for cancer diagnosis and therapy (2025 · Materials Today Bio · 被引 9)
• Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study (2025 · Nature Communications · 被引 7)